Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Jefferies Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Report
November 10, 2016 10:10 AM ESTJefferies reiterated a Hold rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $14.00), following the company's 3Q earnings report. SCMP reported 3Q EPS of $0.28, compared to Jefferies' $0.25 estimate. Revenues of $58M, +$7M ahead of estimates. Based on the Q3... More
